1
|
Koide T, Miyauchi H, Okamoto J, Shidara T, Fujimori A, Fukutani H, Amemiya K, Takeshita H, Yuasa S, Katayama T, Suzuki Y. Direct determination of interfacial magnetic moments with a magnetic phase transition in Co nanoclusters on Au(111). Phys Rev Lett 2001; 87:257201. [PMID: 11736602 DOI: 10.1103/physrevlett.87.257201] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2000] [Indexed: 05/23/2023]
Abstract
The spin, in-plane and out-of-plane orbital and magnetic dipole moments of almost purely interfacial Co atoms were directly determined for Au/2-monolayer Co nanoclusters/Au(111) by angle-dependent magnetic circular x-ray dichroism (MCXD) measurements. The field- and temperature-dependent MCXD evidences a ferromagnetic(FM)-to-superparamagnetic phase transition in single-domain clusters with decreasing size. The interfacial moments are remarkably enhanced as compared with bulk values, verifying theoretical predictions. The FM clusters show strong perpendicular magnetic anisotropy, providing promise of applications for nanoscale magnetic bits.
Collapse
Affiliation(s)
- T Koide
- Photon Factory, IMSS, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Koide T, Miyauchi H, Okamoto J, Shidara T, Sekine T, Saitoh T, Fujimori A, Fukutani H, Takano M, Takeda Y. Close correlation between the magnetic moments, lattice distortions, and hybridization in LaMnO3 and La(1-x)Sr(x)MnO3+delta: doping-dependent magnetic circular X-ray dichroism study. Phys Rev Lett 2001; 87:246404. [PMID: 11736523 DOI: 10.1103/physrevlett.87.246404] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Indexed: 05/23/2023]
Abstract
The first observation of a magnetic circular x-ray dichroism (MCXD) at the Mn L2,3 core edges in antiferromagnetic LaMnO3 shows canted spin and orbital ( m(orb)) moments arising from lattice distortions. An L2,3-edge MCXD in ferromagnetic metals and insulators, La1-xSr(x)MnO3+delta, reveals that m(orb) of Mn strongly depends on x in the metallic regime but remains unchanged with the metal-to-insulator transition (x approximately 0.16). An O K-edge MCXD, which shows m(orb) of O caused by 2p-3d hybridization, is much larger in the ferromagnetic metal than insulator phases, sharply contrasting with m(orb) of Mn. Our findings indicate a close magnetism-lattice-hybridization coupling.
Collapse
Affiliation(s)
- T Koide
- Photon Factory, IMSS, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Shinjo K, Takeshita A, Ohnishi K, Sakura T, Miyawaki S, Hiraoka A, Takeuchi M, Tomoyasu S, Wakita H, Ata K, Fukutani H, Ueda R, Ohno R. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid. Int J Hematol 2000; 72:470-3. [PMID: 11197214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A new synthetic retinoid, Am80, is effective in treating acute promyelocytic leukemia relapsed from all-trans-retinoic acid-induced complete remission (CR). We report here the long-term clinical outcomes of patients who achieved second CR with Am80. Of 24 evaluable patients, 14 achieved a second CR by Am80 therapy. Of those patients, 4 relapsed within 6 months, despite subsequent consolidation chemotherapy. Six patients underwent sibling or unrelated HLA-matched allogeneic bone marrow transplantation (BMT), and 4 are alive without relase for more than 49 months after achieving second CR. Four of 8 patients who did not receive BMT are alive without relapse for more than 49 months. Promyelocytic leukemia-retinoic acid receptor alpha (PML-RAR alpha) fusion transcript was undetectable by reverse transcriptase-polymerase chain reaction in all living patients. Therefore, if patients achieve second CR with Am80 and HLA-matched donors are available, BMT is the treatment of choice. However, it is noteworthy that CR was maintained for more than 49 months in half of the patients who did not receive BMT.
Collapse
Affiliation(s)
- K Shinjo
- Hamamatsu University School of Medicine, Hamamatsu, 3600 Handa-cho, Hamamatsu-shi, 431-3192, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Koide T, Shidara T, Nakajima N, Miyauchi H, Fukutani H. A compact molecular-beam epitaxy apparatus for in situ soft X-ray magnetic circular dichroism experiments. J Synchrotron Radiat 1998; 5:1038-1040. [PMID: 15263737 DOI: 10.1107/s0909049597016129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/1997] [Accepted: 11/10/1997] [Indexed: 05/24/2023]
Abstract
An economical and easily movable molecular-beam epitaxy (MBE) apparatus which prepares magnetic ultrathin films and superlattices with atomically well controlled interfaces has been designed and constructed. Cleaning and characterization of substrates, sample deposition in a layer-by-layer fashion, and characterization of samples both during and after growth can be carried out in a single ultrahigh vacuum (UHV) chamber. This MBE apparatus is combined with UHV high-field magneto-optical instruments for in situ soft X-ray magnetic circular dichroism experiments on two-dimensional magnetic systems.
Collapse
Affiliation(s)
- T Koide
- Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305, Japan
| | | | | | | | | |
Collapse
|
5
|
Koide T, Shidara T, Yamaguchi K, Fujimori A, Fukutani H, Nakajima N, Sugimoto T, Katayama T, Suzuki Y. Core-level magnetic-circular-dichroism study of an Fe single crystal, Fe-Pt alloys, and an Fe/Pt multilayer. Phys Rev B Condens Matter 1996; 53:8219-8222. [PMID: 9982312 DOI: 10.1103/physrevb.53.8219] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
6
|
Kubo K, Yamanaka K, Kiyoi H, Fukutani H, Ito M, Hayakawa R, Ohno R, Naoe T. Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1996; 87:3019-26. [PMID: 8639925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
From the viewpoint of T-cell receptor (TCR) repertoire, we studied the role of T cells in acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (allo-BMT) from an HLA-identical sibling. By means of inverse polymerase chain reaction method and DNA sequencing, we analyzed TCR-alpha and -beta transcripts from GVHD lesions and peripheral blood (PB) in a patient with typical GVHD together with PB from donor. At the initial onset of GVHD, V alpha-7 and -19 subfamilies were oligoclonally expanded in the PB compared with those in the oral mucosal lesions. At the second onset, V alpha-2, and V beta-6 subfamilies were more frequently detected in the cutaneous lesion than in the PB. Some TCR transcripts were recurrently found either in the mucosal or cutaneous lesions (or in both) and not in the PB. Furthermore, some of recurrent TCR transcripts in the lesions shared V gene segments and common motifs of complementarity determining region-3. These findings suggested that T cells infiltrating the GVHD lesions recognized a limited kind of antigens presented by patient's tissues with GVHD, and that T-cell repertoire in the GVHD lesions was different from that in the PB.
Collapse
Affiliation(s)
- K Kubo
- Department of Medicine, The Branch Hospital, Nagoya University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1995; 9:1478-82. [PMID: 7658715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
All-trans retinoic acid (ATRA) has been used as a potent differentiation drug for acute promyelocytic leukemia (APL). Although the mechanism of its effectiveness upon APL remains unclear, the PML-retinoic acid receptor alpha (RARA) chimeric protein produced by t(15;17) is assumed to underlie the sensitivity of APL cells to ATRA. There are two major isoforms of PML-RARA transcripts; short (S) and long (L), according to the breakpoints in the PML gene. We therefore compared the clinical variables, the response to ATRA and the prognosis between 28 patients with type S and 68 patients with type L. Patients were treated in multi-institutional trials with ATRA, and chemotherapy was combined when peripheral blasts and leukocyte counts increased during the therapy. The clinical features at diagnosis were similar between the two molecular subtypes, and there was no significant difference in remission induction rates; 86% for the type S group and 90% for the type L group. There was no statistical difference in overall survival and CR duration as well as disease-free survival (DFS). In newly diagnosed patients, predicted 2-year DFS was 66% for the type S group and 67% for the type L group. In refractory or relapsed patients, it was 19 and 23%, respectively. These data indicated that isoforms of PML-RARA fused transcripts affect neither the clinical features of APL nor the prognosis after treatment with ATRA.
Collapse
Affiliation(s)
- H Fukutani
- Department of Internal Medicine, Nagoya University Branch Hospital, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Yamaguchi K, Namatame H, Fujimori A, Koide T, Shidara T, Nakamura M, Misu A, Fukutani H, Yuri M, Kasaya M, Suzuki H, Kasuya T. Soft-x-ray linear-dichroism and magnetic-circular-dichroism studies of CeRh3B2: Large crystal-field splitting and anomalous ferromagnetism. Phys Rev B Condens Matter 1995; 51:13952-13960. [PMID: 9978319 DOI: 10.1103/physrevb.51.13952] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
9
|
Fukutani H, Naoe T, Ohno R, Yoshida H, Kiyoi H, Miyawaki S, Morishita H, Sano F, Kamibayashi H, Matsue K. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Leukemia 1995; 9:588-93. [PMID: 7723389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Minimal residual disease (MRD) was prospectively monitored at the 10(-5) level by the reverse transcriptase-polymerase chain reaction (RT-PCR) of PML-retinoic acid receptor alpha (RARA) transcripts from 27 acute promyelocytic leukemia (APL) patients who achieved complete remission (CR) with all-trans retinoic acid and chemotherapy (previously untreated patients, 15; refractory to chemotherapy or relapsed, 12). The RNA quality from bone marrow cells was firstly assessed by gel electrophoresis to avoid false negativity because of the fragility of the APL cells and the PML-RARA transcripts. In 12 of 15 untreated patients, RT-PCR became negative during consolidation and intensification therapy 4-16 months after the initiation of therapy, whereas it remained positive in nine of 12 refractory patients. At the end of therapy, RT-PCR was negative in 14 patients and positive in 13 patients. The former patients remained in CR at median follow-up of 9 months after the end of therapy. In the latter, however, 10 patients relapsed at a median of 5 months after the end of therapy. These results suggest that the RT-PCR assay can evaluate the quality of CR in APL and predict subsequent relapse.
Collapse
Affiliation(s)
- H Fukutani
- Department of Internal Medicine, Nagoya University Branch Hospital, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kiyoi H, Fukutani H, Yamauchi T, Kubo K, Ohno R, Yamamori S, Naoe T. Continuing immunoglobulin heavy chain gene rearrangements in chronic myeloid leukemia with recurrent B-lymphoid blast crises after bone marrow transplantation. Leukemia 1995; 9:265-70. [PMID: 7869762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We sequentially analyzed the immunoglobulin heavy chain variable (IgH V) region gene of leukemia cells obtained from a chronic myeloid leukemia (CML) patient who had three episodes of B-lymphoid crisis after bone marrow transplantation. Southern blot analysis using the JH probe showed different rearranged bands at each crisis, although the same rearranged bands of the BCR gene were observed. We amplified and sequenced the IgH V region gene of the leukemia cells by reverse transcriptase polymerase chain reaction (RT-PCR) using the primers corresponding to the consensus 5'VH and mu constant regions. The dominant leukemia clone at each crisis had a unique VH-D-JH rearrangement; VH4A (V79)-DLR2-J5 (clone-1), VH4B (DP70)-DK4-J6 (clone-2) and VH4A (V79)-DN4-J6 (clone-3) at the first, second and third crises, respectively. Further analysis by PCR amplification using the consensus 5'VH and clone-specific primers revealed that clone-1 underwent VH4-->VH3 replacement at the second crisis, and that clone-3 was already in existence at the first crisis. Moreover, the DN4-J6 joining clone, in which the sequence was the same as that of clone-3, was identified at the first and third crises by PCR amplification using primers corresponding to the region upstream of the DN4 segment and DN4-J6 boundary of clone-3. These observations suggest that multiple clones were generated from the progenitor cells of blast crisis, which were transformed at a very early stage of B-lymphocyte ontogeny, by continuing rearrangement mechanisms of the IgH genes, and that the dominant clone at each crisis was undergoing change.
Collapse
MESH Headings
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- B-Lymphocytes/pathology
- Base Sequence
- Blast Crisis/pathology
- Bone Marrow/pathology
- Bone Marrow Transplantation
- Busulfan/administration & dosage
- Clone Cells/pathology
- Cyclophosphamide/administration & dosage
- DNA, Neoplasm/genetics
- Disease Progression
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Genes, Immunoglobulin
- Hematopoietic Stem Cells/pathology
- Humans
- Immunoglobulin Variable Region/genetics
- Immunosuppressive Agents/therapeutic use
- Leukemia, Myeloid, Chronic-Phase/drug therapy
- Leukemia, Myeloid, Chronic-Phase/genetics
- Leukemia, Myeloid, Chronic-Phase/pathology
- Leukemia, Myeloid, Chronic-Phase/surgery
- Male
- Molecular Sequence Data
- Neoplastic Stem Cells/pathology
- Polymerase Chain Reaction
- Testis/pathology
Collapse
Affiliation(s)
- H Kiyoi
- Department of Medicine, Branch Hospital Nagoya University School of Medicine, Japan
| | | | | | | | | | | | | |
Collapse
|
11
|
Yoshida H, Naoe T, Fukutani H, Kiyoi H, Kubo K, Ohno R. Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARA genes within identical short stretches. Genes Chromosomes Cancer 1995; 12:37-44. [PMID: 7534109 DOI: 10.1002/gcc.2870120107] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Molecular analysis of the t(15;17) translocation in 70 patients with acute promyelocytic leukemia (APL) confirmed that the breakpoints of chromosome 15 were located in two regions of the promyelocytic leukemia (PML) gene, mainly introns 3 and 6, whereas the breakpoints of chromosome 17 were consistently in intron 2 of the retinoic acid receptor alpha (RARA) gene. To study the reason for the clustering of the breakpoints and the underlying mechanism of the chromosomal translocation, we characterized the joining sequences of der(15) and der (17) by polymerase chain reaction in samples from eight patients with APL. There was no cluster of the breakpoints within the introns, and no consensus sequence-motif was found around them. One or nine extra nucleotides were inserted into two joining sites. There were identical stretches of one to seven nucleotides between the PML and RARA genes in the majority of the joining sequences. These data provide a potential model of the t(15;17) translocation: random DNA double strand cleavage, modification of DNA ends by enzymes including terminal deoxynucleotidyl transferase, and single strand base-pairing within identical short stretches. Furthermore, APL develops only when the PML and RARA genes are rearranged, within restricted genomic regions and a functional PML-RARA chimeric product is produced, and this might lead to a clustering of the breakpoints.
Collapse
Affiliation(s)
- H Yoshida
- Department of Internal Medicine, Nagoya University Branch Hospital, Japan
| | | | | | | | | | | |
Collapse
|
12
|
Kiyoi H, Fukutani H, Kubo K, Ohno R, Naoe T. Characterization of immunoglobulin heavy chain gene rearrangements in chronic myeloid leukemia with recurrent B-lymphoid blast crisis following bone marrow transplantation. Intern Med 1994; 33:786-9. [PMID: 7718962 DOI: 10.2169/internalmedicine.33.786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
We sequentially analyzed the immunoglobulin heavy chain (IgH) variable region gene of leukemia cells obtained from a chronic myeloid leukemia (CML) patient who had three episodes of B-lymphoid crisis after bone marrow transplantation. Southern blots using the JH probe showed a single rearranged band which differed at each crisis, although the rearranged bands of the BCR gene were the same at each crisis. The IgH variable region sequences of the leukemia cells at each crisis were different. These observations suggested that multiple clones were generated from the progenitor cells of the blast crisis, which were transformed at a very early stage of B-lymphocyte ontogeny.
Collapse
Affiliation(s)
- H Kiyoi
- Department of Medicine, Nagoya University School of Medicine, Aichi
| | | | | | | | | |
Collapse
|
13
|
Kunishima S, Miura H, Fukutani H, Yoshida H, Osumi K, Kobayashi S, Ohno R, Naoe T. Bernard-Soulier syndrome Kagoshima: Ser 444-->stop mutation of glycoprotein (GP) Ib alpha resulting in circulating truncated GPIb alpha and surface expression of GPIb beta and GPIX. Blood 1994; 84:3356-62. [PMID: 7949089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The platelet membrane glycoprotein (GP)Ib/IX complex is composed of three polypeptides, GPIb alpha, GPIb beta, and GPIX, and functions as a platelet receptor for von Willebrand factor. All three subunits are reported to be requisite for efficient surface expression of the complex. The absence of the GPIb/IX complex on platelet membrane is the hallmark of a congenital qualitative platelet disorder, termed the Bernard-Soulier syndrome (BSS). We describe here the molecular basis of a novel variant phenotype of BSS in a female patient, designated as BSS Kagoshima. Her platelets completely lacked the surface expression of GPIb alpha, but expressed a residual amount of GPIb beta and GPIX. Unexpectedly, her platelets and plasma contained a truncated GPIb alpha polypeptide with an apparent molecular weight of 116 kD (under nonreducing conditions). The amounts of truncated protein were 23% and 60% of the normal values in platelets and plasma, respectively. The abnormal protein contained a normal amount of sialic acid as demonstrated by digestion with neuraminidase. DNA sequencing analysis showed a homozygous single nucleotide substitution from the serine codon (TCA) to a nonsense codon (TAA) at residue 444 in the GPIb alpha gene. The mutant gene generated a truncated GPIb alpha molecule lacking the transmembrane region and cytoplasmic tail. Her parents were heterozygotes for the mutation. These findings suggest that this type of truncated GPIb alpha was produced, normally glycosylated, and subsequently secreted into the plasma. Furthermore, the truncated GPIb alpha might be associated with the process of the surface expression of incomplete GPIb/IX complex, GPIb beta and GPIX.
Collapse
Affiliation(s)
- S Kunishima
- Department of Internal Medicine, Nagoya University Branch Hospital, Japan
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Kakizaki A, Fujii J, Shimada K, Kamata A, Ono K, Park K, Kinoshita T, Ishii T, Fukutani H. Fluctuating local magnetic moments in ferromagnetic Ni observed by the spin-resolved resonant photoemission. Phys Rev Lett 1994; 72:2781-2784. [PMID: 10055975 DOI: 10.1103/physrevlett.72.2781] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
15
|
Kubo K, Naoe T, Fukutani H, Ohno R. [New strategy for diagnosis and treatment of acute promyelocytic leukemia with t (15;17)]. Rinsho Ketsueki 1994; 35:250-5. [PMID: 8158844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
All-trans retinoic acid (ATRA)-therapy against acute promyelocytic leukemia (APL) is epoch-making in the sense of the first success in both tumor-differentiation therapy and molecule-targeted therapy. Kouseishou APL-study group performed three clinical studies to refractory APL with ATRA from 1990 to 1993. Complete remission (CR) was obtained in 82%, 88% and 78% of 22, 41 and 46 patients, respectively. Molecular diagnosis of the t (15;17) translocation was possible using Southern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR).
Collapse
MESH Headings
- Chromosomes, Human, Pair 15
- Chromosomes, Human, Pair 17
- Humans
- Leukemia, Promyelocytic, Acute/diagnosis
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Remission Induction
- Translocation, Genetic
- Tretinoin/therapeutic use
Collapse
Affiliation(s)
- K Kubo
- Department of Internal Medicine, Nagoya University Branch Hospital
| | | | | | | |
Collapse
|
16
|
Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Hiraoka A. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. Leukemia 1993; 7:1722-7. [PMID: 8231241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We treated 70 acute promyelocytic leukemia (APL) patients with daily oral 45 mg/m2 all-trans-retinoic acid (ATRA) in two multi-institutional prospective studies. Of 64 evaluable patients, 21 were refractory to initial induction chemotherapy; 10 were refractory to salvage chemotherapy; 17, five, and four were in the first, second and, third relapse, respectively; and seven were previously untreated due to old age. In the first study with ATRA from China, 18 out of 22 (82%) evaluable patients achieved complete remission (CR). Initial peripheral leukemia cell counts were significantly less in the CR cases (p < 0.01); < 100/microliters in 17 out of 18 CR cases, and > or = 200/microliters in all failure cases. In the second study with ATRA from Hoffmann-La Roche, if initial leukemia cell counts were more than 200/microliters, chemotherapy was first given and then ATRA was started. Of 42 evaluable patients, 36 (86%) achieved CR. Morphological evidence of differentiation was noted in all CR cases. Patients achieving CR received standard consolidation and maintenance chemotherapies, and the 20-month predicted disease-free survival rate is 76% for cases achieving their first CR with ATRA. Toxicities attributable to ATRA were minimal and included cheilitis, xerosis, dermatitis, gastrointestinal disorders, bone pain, liver damage, and high serum triglyceridemia.
Collapse
Affiliation(s)
- R Ohno
- Department of Medicine, Nagoya University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ohno R, Naoe T, Fukutani H. [Differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid]. Gan To Kagaku Ryoho 1993; 20:1016-21. [PMID: 8390226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
We treated 70 patients with acute promyelocytic leukemia (APL) with daily oral 45 mg/m2 all-trans retinoic acid (ATRA) in 2 multi-institutional prospective studies. Of 63 evaluable patients, 21 were resistant to initial induction chemotherapy, 10 were resistant to salvage chemotherapy after relapse, 17 were in the first relapse, 4 in the second relapse, 4 in the third relapse, and 7 were previously untreated. In the first study with ATRA from China, 18 (82%) of 22 evaluable patients achieved CR within 8 to 53 days with a median of 29 days. Initial peripheral leukemia cell counts were significantly less in the CR cases (p < 0.01). They were less than 100/mm3 in 17 of 18 CR cases, and more than 200/mm3 in all failure cases. Patients achieving CR received standard consolidation and maintenance chemotherapies, and the 16-month predicted continuing CR rate is 60%. Based on the first study, in the second study with ATRA from Hoffmann-La Roche AG, if initial peripheral leukemia cell counts were more than 200/mm3, chemotherapy was first given and then ATRA was started. Of 41 evaluable patients, 36 (88%) achieved CR within 11 to 91 days with a median of 34 days. Of 3 patients who received preceding chemotherapy due to high leukemia cell counts, 2 achieved CR. Morphological evidence of differentiation was noted in all CR cases, with Auer rods in mature segmented neutrophils in 13 cases. The clinical signs of DIC decreased rapidly within a few days and disappeared in CR cases. Toxicities attributable to ATRA were minimal and included cheilitis, xerosis, dermatitis, gastrointestinal disorders, bone pain, liver damage and high serum triglyceridemia.
Collapse
Affiliation(s)
- R Ohno
- Dept. of Medicine III, Hamamatsu University School of Medicine, Japan
| | | | | |
Collapse
|
18
|
Kubo K, Naoe T, Kiyoi H, Fukutani H, Kato Y, Oguri T, Yamamori S, Akatsuka Y, Kodera Y, Ohno R. Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res 1993; 84:379-87. [PMID: 8514604 PMCID: PMC5919305 DOI: 10.1111/j.1349-7006.1993.tb00147.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
We have screened mutations of the N-ras gene at codons 12, 13, and 61 in leukemia cells obtained from 100 patients with acute myeloid leukemia (AML), and found mutated N-ras alleles in 9 patients. We further analyzed the polyclonality of multiple N-ras gene mutations in 4 AML patients. One patient, who had the monoclonal karyotype, t(11;17), had two types of double missense mutations at codons 13 and 61 in the same allele. Each of the remaining three patients, one of whom had t(15;17) with a monoclonal rearrangement of the retinoic acid receptor alpha and PML genes, carried two missense mutations in a relatively small population of leukemia cells. We have demonstrated that multiple clonality of the N-ras gene is occasionally observed in leukemia with a monoclonal karyotype. These findings indicate that the N-ras mutations may not always be characterized simply by an accumulative process and that the activated N-ras gene alone is not sufficient to cause leukemia.
Collapse
MESH Headings
- Acute Disease
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Base Sequence
- Child
- Child, Preschool
- Cloning, Molecular
- Codon/genetics
- DNA, Neoplasm/genetics
- Female
- Genes, ras/genetics
- Humans
- Karyotyping
- Leukemia, Erythroblastic, Acute/genetics
- Leukemia, Monocytic, Acute/genetics
- Leukemia, Myeloid/genetics
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myelomonocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/genetics
- Male
- Middle Aged
- Molecular Sequence Data
- Point Mutation/genetics
Collapse
Affiliation(s)
- K Kubo
- Department of Internal Medicine, Nagoya University Branch Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Kinoshita T, Ikoma T, Kakizaki A, Ishii T, Fujii J, Fukutani H, Shimada K, Fujimori A, Okane T, Sato S. Evidence for Fano interference in spin polarization of the 6-eV satellite in Ni valence-band photoemission. Phys Rev B Condens Matter 1993; 47:6787-6790. [PMID: 10004661 DOI: 10.1103/physrevb.47.6787] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
20
|
Fukutani H, Naoe T, Yoshida H, Yamamori S, Ohno R. Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance. Jpn J Cancer Res 1993; 84:257-64. [PMID: 8387477 PMCID: PMC5919144 DOI: 10.1111/j.1349-7006.1993.tb02865.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
We determined the breakpoints of the RAR-alpha and PML genes in acute promyelocytic leukemia (APL) cells from 40 patients using Southern blot analysis. We also analyzed the relationship between the location of breakpoints, the clinical features of APL and the response to all-trans retinoic acid (ATRA). While the breakpoints of the RAR-alpha gene were consistently within intron 2, we found two major clusters in the breakpoints of the PML gene. The two breakpoint clusters in the PML gene were separated by 10 kb; 5' breakpoints were in intron 3, and 3' breakpoints were around introns 5 and 6. Twenty percent of the patients had 5' breakpoints in the PML gene and 70% had 3' breakpoints. No rearrangement was observed in the remaining 10% of patients in spite of the presence of t(15;17) translocation. There was no relationship between the location of the PML breakpoints, the clinical features at diagnosis and the response to ATRA.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Base Sequence
- Blotting, Southern
- Carrier Proteins/genetics
- Cell Transformation, Neoplastic/genetics
- Child
- Chromosomes, Human, Pair 15
- Chromosomes, Human, Pair 17
- DNA Probes/genetics
- DNA, Neoplasm/analysis
- Female
- Gene Rearrangement
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Male
- Middle Aged
- Molecular Sequence Data
- Neoplasm Proteins/genetics
- Prevalence
- Receptors, Retinoic Acid
- Restriction Mapping
- Translocation, Genetic
- Tretinoin/pharmacology
Collapse
Affiliation(s)
- H Fukutani
- Department of Internal Medicine, Nagoya University Branch Hospital
| | | | | | | | | |
Collapse
|
21
|
Ichihashi T, Yoshida H, Kiyoi H, Fukutani H, Kubo K, Yamauchi T, Naoe T, Ohno R. Development of hyperthyroidism in donor and recipient after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10:397-8. [PMID: 1422500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
22
|
|
23
|
Ichihashi T, Kiyoi H, Fukutani H, Kubo K, Yamauchi T, Naoe T, Yamada K, Ohno R. Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16. Oncology 1992; 49:333-5. [PMID: 1528567 DOI: 10.1159/000227067] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.
Collapse
Affiliation(s)
- T Ichihashi
- Department of Medicine, Branch Hospital, Nagoya University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Mizunuma N, Ogawa M, Kuraishi Y, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Itami S. [Combination chemotherapy of advanced Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone]. Rinsho Ketsueki 1991; 32:1410-5. [PMID: 1758048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Thirty-three patients with advanced Hodgkin's disease were treated with a combination chemotherapy consisting of vincristine 1 mg/m2 iv on day 1, 8, cyclophosphamide 500 mg/m2 iv on day 1, procarbazine 100 mg/m2 p.o. day 1-7, and prednisolone 40 mg/m2 p.o. day 1-7. Twenty patients received this regimen every 4 weeks (VCPP II regimen). Furthermore, we conducted higher dose intensive VCPP II-2 regimen which was repeated every two weeks for thirteen patients. Complete response rate of both regimens was 63% (VCPP II 45%, VCPP II-2 85%). The median duration of CR was 37 + months. Leukopenia, neurotoxicity and gastrointestinal toxicity were commonly observed but were clinically manageable. These results indicate that high dose intensive chemotherapy is effective for achieving high CR rate for advanced Hodgkin's disease.
Collapse
Affiliation(s)
- N Mizunuma
- Department of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Koide T, Shidara T, Fukutani H, Yamaguchi K, Fujimori A, Kimura S. Strong magnetic circular dichroism at the M2,3 edges in ferromagnetic Ni and ferrimagnetic Fe3O4. Phys Rev B Condens Matter 1991; 44:4697-4700. [PMID: 10000136 DOI: 10.1103/physrevb.44.4697] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
26
|
Fukutani H, Naoe T, Saito H, Ohshima T, Omine M, Miura Y, Mizoguchi H, Kimura I, Tomonaga M, Ohno R. Treatment of myelodysplastic syndromes with orally administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex). Jpn J Clin Oncol 1991; 21:287-92. [PMID: 1942558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex) was administered orally, to patients with myelodysplastic syndromes (MDS) and acute leukemia derived from MDS, in a multi-institute study. Out of 77 patients evaluated, one achieved a complete remission, three a good response and two a partial response while 71 failed to respond to a daily oral administration of 30 mg ubenimex. The overall response rate was 7.8% (95% confidence limits; 3.6-16.0%); 7.0% (3.0-15.4%) in 71 MDS and 16.6% (3.0-56.3%) in acute six leukemias derived from MDS. Responses continued for six to 24 (median 10.5) weeks. No serious hematologic, biochemical or clinical toxicity was encountered, except for gastro-intestinal (GI) toxicity in one patient. The present study demonstrated ubenimex not to be generally beneficial for patients with MDS, and not to be recommended as a standard treatment for the disease.
Collapse
Affiliation(s)
- H Fukutani
- Department of Medicine, Branch Hospital, Nagoya University School of Medicine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Horikoshi N, Ogawa M, Tabata M, Inoue K, Mukaiyama T, Fukutani H, Hirano A, Mizunuma N, Itami S, Oohashi K. [Phase I-II study of hepatic intraarterial one-shot administration of adriamycin in patients with metastatic liver cancer]. Gan To Kagaku Ryoho 1991; 18:977-82. [PMID: 2029200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
For the purpose of obtaining the optimal dose of adriamycin (ADM) in hepatic intraarterial one-shot administration, phase I-II study was conducted in 14 patients with various liver cancers. The starting dose of ADM was 20 mg/m2 (4 patients) and the doses were escalated to 40 mg/m2 (5 patients), 60 mg/m2 (4 patients) and 80 mg/m2 (3 patients). One patient with salivary gland cancer showed PR for the liver metastasis. Major toxicity was leukopenia. With a dose of 40 mg/m2, 3 out of 4 patients showed nadir of WBC counts below 4,000/mm3 (2,400, 2,900, 3,100), 60 mg/m2 (1,100, 1,500, 2,200 and 2,700), and 80 mg/m2 (900, 1,200, and 1,400). Nadirs of WBC counts were observed from 9 to 15 days after the one-shot administration, and recovered above 4,000/mm3 in 1 to 3 weeks. Plasma concentrations of ADM from the peripheral vein were determined by HPLC in 12 patients, 14 courses. The curves of ADM plasma levels after 20 and 40 mg/m2 bolus injections were almost the same, and in patients treated with 60 and 80 mg/m2 the curves were also quite similar, but higher in the plasma levels, comparing with in patients with 20 and 40 mg/m2. There might be a limit of ADM tissue absorption, and above the doses 60 mg/m2, ADM might be overflowed, followed by side effects, especially leukopenia. Upon these data of venous plasma concentrations of ADM and leukopenia, the optimal dose of ADM in the hepatic intraarterial one-shot administration seemed to be 40 mg/m2.
Collapse
Affiliation(s)
- N Horikoshi
- Dept. of Clinical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Fukutani H, Naoe T, Ohno R. [Is allogeneic bone marrow transplantation the first choice for acute leukemia in first remission? From chemotherapeutical point of view]. Rinsho Ketsueki 1991; 32:361-5. [PMID: 2067079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Since 1984 several prospective randomized clinical trials have been reported that the disease-free survival for BMT in first remission was superior to chemotherapy for AML. However, there raise two main controversies about these conclusions. First, in last several years intensive consolidation therapy was applied and nearly 50% of patients are reported to be alive 5 years. Second 10% to 50% BMT scheduled patients were excepted mainly because of their condition. On the contrary, about ALL, even these several years, age is the still main risk factor independently of therapy. Reports with good 5 year disease free survival all due to their patients' youth. The prognosis of ALL patients age 30 or more are poor and BMT seems to be a first choice in first-remission in patients under age 40. Only large-scale prospective randomized study among patients with or without HLA-identical donors will give the answer to this important issue.
Collapse
Affiliation(s)
- H Fukutani
- Department of Medicine, Nagoya University School of Medicine
| | | | | |
Collapse
|
29
|
Koide T, Shidara T, Fukutani H, Fujimori A, Miyahara T, Kato H, Otani S, Ishizawa Y. Optical study of the stoichiometry-dependent electronic structure of TiCx, VCx, and NbCx. Phys Rev B Condens Matter 1990; 42:4979-4995. [PMID: 9996057 DOI: 10.1103/physrevb.42.4979] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
30
|
Itami S, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Mizunuma N, Nakagawa K. [Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer]. Gan To Kagaku Ryoho 1990; 17:1015-20. [PMID: 2159265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Twenty patients with advanced non-small cell lung cancer were treated with a combination chemotherapy consisting of ifosfamide (IFX), cisplatin (CDDP) and vindesine (VDS). The treatment schedule was IFX 1.3 g/m2 i.v., on days 1-5, CDDP 20 mg/m2 i.v., on days 1-5, and VDS 3 mg/m2 i.v., on days 1 & 8, and, in principle, the regimen was repeated every 4 weeks. Of 19 evaluable patients, there were 1 CR, 7 PR, 10 NC and 1 PD, with an overall response rate of 42.1%. The median duration of responses was 7.45 months, and the median survival time of all patients was 13.2 months. The major toxicities occurring were hematologic toxicity, alopecia, gastrointestinal toxicity and peripheral neuropathy. Hematologic toxicity was severe and was judged to be dose limiting, but clinically manageable. These results indicate that this combination chemotherapy is active against non-small cell lung cancer and deserves further studies.
Collapse
Affiliation(s)
- S Itami
- Dept. of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Borghesi A, Piaggi A, Guizzetti G, Lévy F, Tanaka M, Fukutani H. Optical properties of single-crystal titanium disilicide. Phys Rev B Condens Matter 1989; 40:1611-1615. [PMID: 9992016 DOI: 10.1103/physrevb.40.1611] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
32
|
Tabata M, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Fukutani H, Hirano A, Mizunuma N. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline]. Gan To Kagaku Ryoho 1989; 16:2361-6. [PMID: 2546503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Phase I clinical trial of a new semi-synthetic morpholino anthracycline derivative, KRN8602, was performed. Sixteen patients with advanced malignant neoplasms refractory to standard chemotherapies received 27 courses at doses ranging from 1.5 mg/m2/day to 18 mg/m2/day by bolus injection for three consecutive days. The dose limiting toxicity was leukopenia, and a maximally tolerated dose was 18 mg/m2/day (day 1-3). The recommended dose and schedule for a phase II study is determined to be 12 mg/m2/day for three consecutive days at 3-4 weeks intervals. Among non-hematologic toxicities, nausea and vomiting were severe, but stomatitis and alopecia were rarely observed. Clinical signs of cardiotoxicity were not seen.
Collapse
Affiliation(s)
- M Tabata
- Dept. of Clinical Oncology, Japanese Foundation for Cancer Research, Tokyo
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Mukaiyama T, Ogawa M, Horikoshi N, Inoue K, Fukutani H, Tabata M, Hirano A, Mizunuma N, Itami S. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults]. Gan To Kagaku Ryoho 1989; 16:2019-23. [PMID: 2730091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Eight patients with acute non-lymphocytic leukemia in adults refractory to Daunomycin (DM)-based conventional regimens were treated with AMSA-based regimens. Complete remission (CR) was obtained in 4 (50%) and partial remission (PR) in 2 (25%). The median time to CR was 26.5 days and 3 cases achieved CR in the first cycle. The median duration of CR was 8.3 months. Hematologic toxicity was severe and the nadir (median) of leukocytes and platelets was 0.15 x 10(3)/microliters and 15.5 x 10(3)/microliters, respectively. Other adverse effects were mucositis, nausea.vomiting and hepatotoxicity which occurred over 50%, while cardiac toxicity was not observed. This study indicates that AMSA is clinically non-cross-resistant to DM and considered to be an active drug for salvage therapy.
Collapse
Affiliation(s)
- T Mukaiyama
- Dept. of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Fukutani H, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Tabata M, Hirano A, Mizunuma N. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study]. Gan To Kagaku Ryoho 1989; 16:2005-12. [PMID: 2471461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Seventeen patients with advanced malignancy were treated with recombinant human granulocyte colony stimulating factor rhG-CSF (KRN 8601) infused intravenously over a period of 30 minutes once daily at the dose level/25 micrograms, 50 micrograms, 100 micrograms, 200 micrograms, 400 micrograms, 800 micrograms/m2 for 14 consecutive days, and the effect was compared to the period without rhG-CSF treatment. The maximum numbers of peripheral leukocyte (granulocyte) showed a dose-related increase and the nadir of leukocyte counts escalated with shortening of the period. After stopping infusion, the neutrophil count dropped to the base line level within two or three days. RhG-CSF did not affect other components of peripheral blood such as monocyte, lymphocyte, eosinophil, and hemoglobin value and platelet counts. Transient bone pain occurred in two patients receiving a dose of 800 micrograms/m2. The biochemical changes detected were increased total alkaline phosphatase activity in serum, which appeared in parallel with the increase of neutrophil numbers, and less elevation of total uric acid values. We conclude that an optimal dose of rhG-CSF is 100 micrograms/m2 (average maximum peripheral granulocyte count, 10799/microliters; nadir granulocyte count, 3772/microliters; period of neutropenia, 2.6 days), and rhG-CSF is useful for acceleration of neutrophil recovery and prevention of infection from chemotherapy.
Collapse
Affiliation(s)
- H Fukutani
- Dept. of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Mukaiyama T, Ogawa M, Horikoshi N, Inoue K, Fukutani H, Tabata M, Hirano A, Mizunuma N, Itami S. [A study to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation]. Gan To Kagaku Ryoho 1989; 16:2013-8. [PMID: 2471462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Drug resistant phenomenon to antitumor agents remains a major problem in cancer chemotherapy. In this study, we attempted to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation (ABMT). The main regimen consisted of Cyclophosphamide 60 mg/kg/day and thio-TEPA 6 mg/kg/day which were infused for 3 consecutive days. Three patients with malignant lymphoma, four with breast cancer, two with gastric cancer and one with ovarian cancer. All of whom were refractory to conventional chemotherapies were treated. The overall response rate was 70%. Severe bone marrow suppression, mucositis and diarrhea were observed in all patients, but these were not life-threatening and clinically manageable. Furthermore, the administration of granulocyte colony stimulating factor (G-CSF) has significantly (p less than 0.05) shortened the duration of leukopenia, and has been judged to be useful for reducing severe infections and for shortening the period stayed in clean room. Our results indicates that high-dose chemotherapy with ABMT is an effective method for overcoming drug resistance.
Collapse
Affiliation(s)
- T Mukaiyama
- Dept. of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Shinagawa K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Mizunuma N. [A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy]. Gan No Rinsho 1989; 35:581-6. [PMID: 2541272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Twenty-eight patients with a metastatic breast cancer who have achieved a complete remission from a combination chemotherapy that included doxorubicin have been analyzed to ascertain the factors which affect the duration of the response and the survival time. The median duration of a complete remission was 26 months. Relapses occurred in 17 patients (61%), of which the median duration of the response was 18 months and 71% of the relapses occurred at the sites of the prior dominant disease. Most of the patients suffered a relapse while they were receiving maintenance chemotherapy. The number of metastasized organs were one or two in 89% of the patients. The dominant sites of the disease were mainly the visceral (61%) and soft tissue (29%), and the duration of survival was found to be longer in patients with a visceral metastasis. In the group of patients who experienced a recurrence 2 years or more after their operation showed a statistically longer remission and survival time than those who experienced a recurrence within 2 years. The duration of survival from the start of chemotherapy was 45.5 months for complete responders and 21 months for partial responders. This difference was statistically significant (p less than 0.001), though no difference was found between partial responders and "no-change" patients (18.5 months). The tendency towards a relapse at the site of the initial involvement and while receiving maintenance therapy suggests that the majority of patients with a metastatic breast cancer who achieved a complete remission with this combination chemotherapy still have a substantial subclinical residual tumor. Maintenance treatment should be investigated to ascertain the procedures and duration of therapy. Thus, these results have indicated that it is necessary to achieve a complete remission in order to obtain a long term survival.
Collapse
Affiliation(s)
- K Shinagawa
- Div. of Clinical Chemotherapy, Japanese Foundation for Cancer Research Cancer Chemotherapy Center
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Watanabe N, Sakabe K, Sakabe N, Higashi T, Sasaki K, Aibara S, Morita Y, Yonaha K, Toyama S, Fukutani H. Crystal structure analysis of omega-amino acid:pyruvate aminotransferase with a newly developed Weissenberg camera and an imaging plate using synchrotron radiation. J Biochem 1989; 105:1-3. [PMID: 2500426 DOI: 10.1093/oxfordjournals.jbchem.a122600] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The three-dimensional structure of omega-amino acid:pyruvate aminotransferase from Pseudomonas sp. F-126, an isologous alpha 4 tetramer containing pyridoxal 5'-phosphate (PLP) as a cofactor, has been determined at 2.0 A resolution. The diffraction data were collected with a newly developed Weissenberg camera with a Fuji Imaging Plate, using synchrotron radiation. The mean figure-of-merit was 0.57. The subunit is rich in secondary structure and comprises two domains. PLP is located in the large domain. The high homology in the secondary structure between this enzyme and aspartate aminotransferase strongly indicates that these two types of enzymes have evolved from a common ancestor.
Collapse
Affiliation(s)
- N Watanabe
- Institute of Physics, University of Tsukuba, Ibaraki
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Shinagawa K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Mizunuma N. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. Gan To Kagaku Ryoho 1988; 15:3277-81. [PMID: 3143311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy). The therapy was repeated every 3 weeks until progression or until a cumulative dose of 700 mg/m2 for epirubicin. Of 25 evaluable patients, there were one with complete response (CR), 11 with partial response (PR), 10 with no change and 3 with progressive disease (PD). The overall response rate (CR + PR) was 48%, and the median duration of response was 47 weeks. The median survival time was 78 weeks for responders and 60 weeks for non-responders, and the difference was statistically significant (p = 0.02). Leukopenia, alopecia, nausea and vomiting were commonly observed, but these side effects were better tolerated than those accompanying ACF therapy. As for cardiotoxicity, there were no acute abnormal E.C.G. changes and no congestive heart failure occurred. The median cumulative dose of Epirubicin was 510 mg/m2. These results indicate that ECF therapy is as effective as ACF therapy for metastatic breast cancer with considerably better tolerability.
Collapse
Affiliation(s)
- K Shinagawa
- Japanese Foundation for Cancer Research, Division of Clinical Chemotherapy, Tokyo
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Fujimori A, Miyahara T, Koide T, Shidara T, Kato H, Fukutani H, Sato S. 4f-derived photoemission and 4f-ligand hybridization in light rare-earth halides. Phys Rev B Condens Matter 1988; 38:7789-7795. [PMID: 9945508 DOI: 10.1103/physrevb.38.7789] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
|
40
|
Takeyama H, Fukutani H, Takeo T, Yamada H, Watanabe E. [Intermediate-dose cytosine arabinoside in combination with mitoxantrone in the treatment of refractory leukemia]. Rinsho Ketsueki 1988; 29:1050-4. [PMID: 3184471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
41
|
Watanabe E, Fukutani H, Yamada H, Takeyama H, Yokomaku S, Kawashima K, Ohno R, Hirano M. [Prognostic factors of chronic myelocytic leukemia--multivariate life table analysis of CML]. Nihon Ketsueki Gakkai Zasshi 1988; 51:582-6. [PMID: 3048033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
42
|
Yamada H, Takeyama H, Fukutani H, Watanabe E, Saka Y, Suzuki K, Kameyama Y, Esaki J, Yamazaki H, Mori Y. [Serotype and susceptibilities to eight antibiotics of fifty strains of Pseudomonas aeruginosa isolated from clinical specimens and changes in susceptibilities of Pseudomonas aeruginosa to various antibiotics during a period between 1983 and 1986]. Jpn J Antibiot 1988; 41:469-77. [PMID: 3145990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Efficacies of 8 antibiotics against Pseudomonas aeruginosa in the relation to serotypes and clinical sources were investigated on 50 strains isolated from patients at Nagoya Ekisaikai Hospital between August and September, 1986. Disk sensitivity test was carried out simultaneously for 5 antibiotics including piperacillin (PIPC), cefoperazone (CPZ), cefsulodin (CFS), ceftazidime (CAZ) and amikacin (AMK), using the single-disk method. We also examined changes in susceptibilities of P. aeruginosa to 5 antibiotics including PIPC, CFS, fosfomycin, gentamicin (GM) and AMK during last 4 years (1983-1986). The results are summarized as follows. 1. CAZ and AMK proved to have high antibacterial potencies, and their MIC80's (concentrations to inhibit growth of 80% of objective bacteria) were both 6.25 micrograms/ml. Following these two the order of potencies were; CFS, cefpiramide (CPM), PIPC, CPZ, netilmicin (NTL), and cefmenoxime (CMX). Sixty two percent of the strains of P. aeruginosa showed high resistances (MIC greater than 50 micrograms/ml) to CPM, CPZ, NTL and CFS, 58% to PIPC, and 2% to AMK. 2. With regard to serotypes, strains belonging to type E were less susceptible than those belonging to types G and I. Type E strains showed high resistance to all antibiotics except CAZ and AMK. 3. Strains obtained from pura and secreta were relatively susceptible, while those from urines were resistant, to these antibiotics tested, in general. 4. Good correlation between MIC's obtained with the agar dilution method (MIC less than or equal to 12.5 micrograms/ml) and these with the disk sensitivity test (greater than ¿ was observed. chi 2 statistical analysis showed that the results obtained with the 2 methods were closely related (P less than 0.01). 5. P. aeruginosa showed fairly high susceptibility to AMK through the recent 4 years (1983-1986). On the other hand, highly resistant strains against CFS, PIPC, FOM and GM increased rapidly during this period.
Collapse
Affiliation(s)
- H Yamada
- Department of Internal Medicine, Nagoya Ekisaikai Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Yamada H, Takeyama H, Watanabe E, Fukutani H, Saka Y, Suzuki K, Kameyama Y, Esaki J, Yamazaki H, Mori Y. [In vitro combination effects of astromicin and beta-lactam antibiotics against CFS-sensitive and CFS-resistant Pseudomonas aeruginosa. In vitro synergistic activity]. Jpn J Antibiot 1988; 41:478-84. [PMID: 3145991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
We investigated in vitro synergistic activity of astromicin (ASTM) combined with beta-lactam antibiotics (cefsulodin (CFS), cefoperazone (CPZ), ceftazidime (CAZ), piperacillin (PIPC) and fosfomycin (FOM) against fresh clinical isolated Pseudomonas aeruginosa, which consisted of 13 CFS sensitive (MIC less than or equal to 3.13 micrograms/ml) and 19 CFS resistant (MIC greater than or equal to 400 micrograms/ml) strains according to the FIC index. Against CFS-sensitive P. aeruginosa, ASTM showed good synergistic activities when combined with PIPC (54%), CAZ (38%), CPZ (23%) and CFS (8%). Against CFS-resistant P. aeruginosa, ASTM also showed high synergistic activities when combined with CAZ (63%), CPZ (47%), PIPC (37%) and CFS (11%). Among the CFS-resistant P. aeruginosa, one clinical isolate showed a high sensitivity (MIC0.78 micrograms/ml) against ASTM alone.
Collapse
Affiliation(s)
- H Yamada
- Department of Internal Medicine, Nagoya Ekisaikai Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Takeyama H, Yamada H, Fukutani H, Takeo T, Watanabe E, Satake T. [Basophilic crisis of chronic myelogenous leukemia without splenomegaly]. Rinsho Ketsueki 1988; 29:389-94. [PMID: 3165145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
45
|
Imajo K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Ozeki H, Nagamine D, Shinagawa K, Fukutani H. [Adriamycin, cyclophosphamide, ftorafur and tamoxifen (ACFT) in patients with advanced breast cancer]. Gan To Kagaku Ryoho 1988; 15:121-6. [PMID: 3122665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
One hundred and six patients with advanced breast cancer were treated with chemoendocrine therapy consisting of adriamycin (40 mg/m2) i.v. on day 1 and cyclophosphamide (130 mg/m2) i.v. daily for 5 days every 3 weeks, ftorafur (500 mg/m2) and tamoxifen (40 mg) orally daily. Of 82 evaluable patients, 16 showed complete response (20%), 32 partial response (39%), 32 no change (39%), and two progressive disease (2%). The overall response rate was 59%, and the median duration of response was 16.3 (3.5-67+) months with a median survival time from the start of chemoendocrine therapy of 25.5 (3.5-67+) months. The median survival time of responders (32.5 months) was significantly longer than that of non-responders (15.3 months). The major toxicities were hair loss, G1 symptoms, and hematological toxicity, but these were clinically well tolerated. No serious cardiac, renal or liver damage was seen. These results indicated that the addition of tamoxifen to the ACF regimen increased the number of complete responses and prolonged the survival time of responders.
Collapse
Affiliation(s)
- K Imajo
- Dept. of Clinical Oncology, Cancer Institute Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Koide T, Yanagihara M, Aiura Y, Sato S, Shidara T, Fujimori A, Fukutani H, Niwano M, Kato H. Resuscitation of carbon-contaminated mirrors and gratings by oxygen-discharge cleaning. in the 4-40-eV range. Appl Opt 1987; 26:3884-3894. [PMID: 20490158 DOI: 10.1364/ao.26.003884] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The dc oxygen-discharge cleaning of optical elements contaminated by synchrotron radiation has been studied for a variety of contamination levels, optical materials, electrode and reflecting-surface configurations, discharge powers, and exposure times. Cleaning with a proper electrode-surface configuration resulted in the removal of contaminant layers within 1 h even for highly contaminated elements. The reflectance of mirrors and the diffraction efficiency of gratings were almost completely restored after cleaning over the 4-40- eV energy range; the enhancement even amounted to 1 order of magnitude in some cases. This cleaning procedure did not cause any increased roughness; rather, it resulted in a reduced scattering level of contaminated elements. The removal of contaminants also led to a restoration of the grating blaze; essentially, this contributed to an improvement in the inside first-order efficiency around the blazed energy. From the results with controlled power and exposure time, it was shown that an optimum exposure is achieved within several minutes after the disappearance of visible contamination.
Collapse
|
47
|
Takeyama H, Yano K, Fukutani H, Watanabe E. [A preliminary study of chemo-interferon therapy in malignant lymphoma]. Gan To Kagaku Ryoho 1987; 14:140-5. [PMID: 3800402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Clinical studies of combination therapy with chemotherapeutic agents and interferon (IFN) were performed. Seventeen patients with non-Hodgkin's lymphoma (NHL) and 2 patients with Hodgkin's disease (HD) were treated by combination chemotherapy (COPP or CHOP), and then received 300 X 10(4) U of alpha-IFN daily for 14 days. Complete remission was seen in 11 of 15 evaluable patients with NHL and both of 2 patients with HD. Myelosuppression such as leukopenia and thrombocytopenia was observed in half of the patients. Other side effects were fever, liver dysfunction, alopecia, and peripheral neuropathy. However, all these side effects were mild and well tolerated even in elderly patients.
Collapse
|
48
|
Takeyama H, Yano K, Fukutani H, Yamamoto F, Watanabe E, Satake T. [Reduction of Ph1 chromosome in atypical myeloproliferative disorder by intensive chemotherapy]. Rinsho Ketsueki 1986; 27:1640-4. [PMID: 3468279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
49
|
Takeyama H, Kataoka T, Yano K, Fukutani H, Watanabe E. [Mucosal injury of aclacinomycin A in patients with adult acute leukemia--comparison of BH-AC. AMP therapy and BH-AC. DMP therapy]. Rinsho Ketsueki 1986; 27:508-13. [PMID: 3461186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
50
|
|